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Abstract
Recently, three large randomized clinical trials: REVERSE, MADIT-CRT, and RAFT were
completed aiming to determine the effects of cardiac resynchronization therapy (CRT) or CRT
with defibrillator (CRT-D) in less advanced, predominantly NYHA class II heart failure (HF)
patients. The REVERSE trial, significantly smaller than the other two trials, could be consi-
dered as a phase II study indicating that mild-to-moderate HF patients show symptomatic and
hemodynamic improvement in response to CRT. The MADIT-CRT and RAFT are considered
as definitive trials with large patient populations of about 1,800 patients each, and HF event/
/hospitalization or death as the primary endpoint. Both trials showed a significant reduction
in the risk of primary endpoints: a 34% reduction in MADIT-CRT and 25% reduction in
RAFT. However, RAFT also showed a significant reduction in mortality which was not
observed in MADIT-CRT. The clinical characteristics of patients studied in both trials were
different despite somewhat similar entry criteria. RAFT enrolled more advanced HF patients
(including 20% NYHA class III patients) than MADIT-CRT. In the CRT-D arm, RAFT
patients had about 20% two-year mortality in comparison to approximately 6% two-year
mortality in MADIT-CRT. Mortality in RAFT was in similar to those observed in CRT-D
patients in the COMPANION trial (estimated 25% two-year mortality), and in the CRT arm
of the CARE-HF trial (estimated 18% two-year mortality), both older studies which enrolled
NYHA class III and IV HF patients. Based on the above comparison, one could conclude that
RAFT enrolled moderate-to-advanced HF patients whereas MADIT-CRT enrolled truly mild-
-to-moderate patients. (Cardiol J 2010; 17, 6: 543–548)
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Introduction
Heart failure (HF) patients with decreased
ejection fraction (EF), New York Heart Association
(NYHA) class III or IV, and a wide QRS (≥ 120 ms)
derive significant benefit from cardiac resynchro-
nization therapy (CRT) measured by HF hospitali-
zation and death as the primary endpoints [1–3].
CRT improves functional status and quality of life
but even more importantly decreases the risk of HF
hospitalization and mortality.
The Comparison of Medical Therapy, Pacing,
and Defibrillation in Heart Failure (COMPANION)
trial enrolled 1,520 HF patients with an EF £ 35%,
NYHA class III or IV, QRS ≥ 120 ms who were ran-
domized to conventional pharmacologic therapy or
CRT with either a pacemaker (CRT-P) or a pace-
maker-defibrillator (CRT-D) [1]. CRT-P decreased
the risk of death or hospitalization for any cause by
19% (hazard ratio: 0.81; p = 0.014) and CRT-D by
20% (hazard ratio: 0.80; p = 0.01). Hospitalization
for HF or death was reduced respectively by 34%
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(p < 0.002) and by 40% (p < 0.001). Mortality was
decreased by 24% by CRT-P (p = 0.059) and by 36%
by CRT-D (p = 0.003).
The Cardiac Resynchronization-Heart Failure
(CARE-HF) Study involved 813 HF NYHA class III
or IV patients with an EF £ 35% who were randomi-
zed to conventional medical therapy or CRT-P
(without defibrillator) [2]. The primary endpoint was
a composite of death from any cause or an unplanned
hospitalization for a major cardiovascular event. The
use of CRT-P significant reduced this primary end-
point by 37% (hazard ratio: 0.63; p < 0.001) and mor-
tality by 36% (hazard ratio: 0.64; p < 0.002). Both
of these studies formed the basis for clinical indi-
cations for CRT, thus recommending that HF pa-
tients with NYHA class III or IV, EF £ 35% and
QRS ≥ 120 ms should be treated with CRT-D de-
vices.
However, the vast majority of HF patients
with depressed EF remain in less advanced stag-
es of HF. Therefore it is even more important to
prevent progression of HF in patients mild to mode-
rate HF, namely NYHA class I and II. The ques-
tion regarding the benefits of CRT therapy in such
less advanced patients was raised by investigators
designing and conducting three large randomized
clinical trials: REVERSE, MADIT-CRT, and RAFT
(Table 1).
Table 1. Comparison of clinical trials evaluating clinical effects of cardiac resynchronization therapy in
mild to moderate heart failure.
Trial REVERSE REVERSE MADIT-CRT RAFT
European
Number of patients 610 262 1,820 1,798
Design of trial
Inclusion criteria:
NYHA class I/II I/II I/II II/III
EF £ 40% £ 40% £ 30% £ 30%
QRS ≥ 120 ms ≥ 120 ms ≥ 130 ms ≥ 120 ms/
/≥ 200 ms paced
Primary endpoint HF clinical HF clinical HF event HF hospitalizations
composite score composite score or death or death
Intervention CRT-D or CRT CRT-D or CRT CRT-D vs ICD (3:2) CRT-D vs ICD (1:1)
vs no CRT (2:1) vs no CRT (2:1)
Results of trial
Follow-up 12 months 24 months 28 months 40 months
NYHA class:
I 18% 17% 15% –
II 82% 83% 85% 80%
III – – – 20%
Mean EF 27% 28% 24% 23%
Mean QRS 153 ms 153 ms 158 ms 158 ms
Left bundle branch block NR NR 70% 72%
HF or death:
Comparison arm NR 24%* 25.3% 40.3%
CRT/CRT-D arm NR 12%* 17.2% 33.2%
Hazard ratio (p value) NR 0.38 (0.003) 0.66 (0.001) 0.75 (< 0.001)
HF hospitalization:
Comparison arm 7% 18.4% 22.8% 26.1%
CRT/CRT-D arm 3% 7.8% 13.9% 19.5%
Hazard ratio (p value) 0.47 (0.03) 0.39 (0.01) 0.59 (< 0.001) 0.68 (< 0.001)
Death:
Comparison arm 2.2% 8.6% 7.3% 26.1%
CRT/CRT-D arm 1.6% 5.7% 6.8% 20.8%
Hazard ratio (p value) NR (0.63) 0.40 (0.09) 1.00 (0.99) 0.75 (0.003)
*Estimated from the figure; CRT — cardiac resynchronization therapy; ICD — implantation cardioverter-defibrillator; NR — not reported;
NYHA — New York Heart Association class; EF — ejection fraction; HF — heart failure
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REVERSE
Resynchronization Reverses Remodeling in
Systolic Left Ventricular Dysfunction (REVERSE)
trial enrolled 610 NYHA class II patients and class I
patients with previous HF symptoms, with QRS
≥ 120 ms and EF £ 40% [4]. This trial did not use
classical HF hospitalization or death endpoint due
to its limited sample size. Instead, the primary end-
point was the HF clinical composite response that
scored patients as improved, unchanged, or wors-
ened over a relatively short follow-up of 12 months.
The study did not meet the primary endpoint: 16%
of patients worsened in the CRT-ON compared with
21% in the CRT-OFF (p = 0.10) group. In seconda-
ry analyses, the time-to-first HF hospitalization
during 12-month follow-up was significantly delayed
in the CRT-ON group (hazard ratio: 0.47, p = 0.03).
European investigators of this trial followed
262 of the patients up to 24 months and the prima-
ry endpoint of worsening was found to be signifi-
cantly lower in the CRT-ON group than in the CRT-
-OFF group (19% vs 34%, respectively, p = 0.01)
[5]. Time to first HF hospital stay or death in the
European cohort was significantly delayed by CRT
(hazard ratio: 0.38; p = 0.003). The REVERSE trial
was not designed to answer the question about the
effect of CRT on HF hospitalization or death. Further-
more, it allowed for both CRT-P and CRT-D therapy
making the applicability of findings more difficult re-
garding effects of this therapy on mortality.
MADIT-CRT
The Multicenter Automatic Defibrillator Im-
plantation Trial-Cardiac Resynchronization Thera-
py (MADIT-CRT) trial was the first large randomi-
zed trial that was designed to determine whether
CRT-D therapy vs ICD only therapy will reduced
the risk of the clinical endpoint of a HF event or
death in mild to moderate HF patients [6]. A HF
event was defined as HF hospitalization (account-
ing for 87% of HF events) or outpatient HF man-
agement (accounting for the remaining 13% of HF
events). The trial enrolled 1,820 ischemic (NYHA
class I or II) and nonischemic (class II) cardiomyo-
pathy patients with EF £ 30% and QRS ≥ 130 ms.
The primary endpoint occurred in 17.2% of patients
randomized to CRT-D and 25.3% to ICD only the-
rapy: a 34% reduction in the risk of HF event or
death (hazard ratio in the CRT-D group: 0.66; p =
= 0.001). Figure 1 shows Kaplan-Meier estimates
of the probability of survival free of HF in CRT-D
versus ICD in the MADIT-CRT trial. This effect was
dominated by a significant 41% reduction in the risk
of HF events whereas there was no significant dif-
ference in mortality between the CRT-D and ICD-
-only arms.
Patients with a wide QRS duration ≥ 150 ms
as well as females had significantly more benefit
from CRT-D than patients with QRS < 150 ms and
males [6]. Further analyses revealed that patients
with left bundle branch block (LBBB), accounting
Figure 1. Kaplan-Meier estimates of the probability of survival free of heart failure in CRT-D vs ICD in the MADIT-CRT
(reproduced from reference [6] with permission).
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for 70% of the enrolled patients, derived a signifi-
cant benefit from CRT-D whereas patients with
a wide QRS complex and right bundle branch block
(RBBB) or indeterminate ventricular conduction
disturbances (IVCD) (regardless of QRS duration)
did not demonstrate reduction in primary events [7,
8]. Hazard ratios for comparing CRT-D vs ICD only
groups regarding the primary endpoint were signi-
ficantly (p < 0.001) lower in LBBB patients (hazard
ratio: 0.47; p < 0.001) than in non-LBBB (RBBB
or IVCD) patients (hazard ratio: 1.24; p = 0.257)
[8]. These observations led to the approval of new
CRT-D indications by the Food and Drug Adminis-
tration [9], which cover not only NYHA class III and
IV patients but also NYHA class II or ischemic class I
HF patients with QRS duration ≥ 130 ms, EF £ 30%
and LBBB.
RAFT
The recently presented and published results
of the Resynchronization/Defibrillation in Advance
Heart Failure Trial (RAFT) provide further evi-
dence supporting these new indications [10]. RAFT
enrolled 1,798 NYHA class II or III HF patients with
an EF £ 30% and an intrinsic QRS ≥ 120 ms or
a paced QRS ≥ 200 ms, and randomized them 1:1
to an implantable cardioverter-defibrillator (ICD)
alone or an ICD plus CRT (CRT-D). Similarly to the
MADIT-CRT trial, the primary endpoint was defined
as hospitalization for HF or death. The risk of pri-
mary endpoint was significantly reduced by 25%
(hazard ratio: 0.75; p<0.001), from 40.3% in the ICD-
-only group to 33.2% in the CRT-D group (Fig. 2).
At the same time, mortality was also reduced by 25%
(hazard ratio: 0.75; p = 0.003), from 26.1% in the
ICD-only patients to 20.8% in CRT-D patients. Since
the RAFT trial enrolled 80% of patients with NYHA
class II and 20% with NYHA class III, the authors
performed additional analyses in these two sub-
groups, which showed that when the analysis was
confined to just NYHA class II patients, a reduction in
cardiac events was still significant: 27% reduction in
primary endpoint, 29% reduction in mortality (Fig. 3).
Additional subgroup analyses demonstrated signi-
ficant interaction terms for QRS duration ≥ 150 ms
and for QRS morphology indicating that patients with
wide QRS benefit from CRT-D therapy significantly
more than patients with QRS < 150 ms and that pa-
tients with LBBB benefit more than patients with
RBBB, IVCD or paced QRS. Females also showed
a trend toward more significant benefit than men.
Comparison of REVERSE,
MADIT-CRT, and RAFT
The REVERSE trial is difficult to compare with
the MADIT-CRT and RAFT trials since it is a rela-
tively small trial with a limited number of patients
and limited follow-up which did not specify cardiac
Figure 2. Kaplan-Meier estimates of hospitalization for heart failure or death in the RAFT (reproduced from reference
[10] with permission).
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events (HF or death) as the primary endpoint of the
study. As originally designed, REVERSE trial did
not meet the primary endpoint of change in HF or
clinical status. The study met the secondary end-
point: significant reduction in the left ventricular
(LV) end-systolic volume index associated with
CRT. Nevertheless, tertiary analyses of HF hospi-
talization showed a significant reduction in CRT-
-treated patients in comparison to non-CRT patients.
The REVERSE trial should be considered as
a phase II trial, designed with a short follow-up and
secondary type endpoints. Follow-up extended to
24 months in the European REVERSE trial patients
demonstrated that the primary endpoint of HF sta-
tus improvement and reduction in LV volumes were
found significant, as well as the clinical endpoint of
HF hospitalization and HF hospitalization or death
were also significantly reduced in CRT-ON vs CRT-
-OFF patients. It is important to stress that in com-
parison to the MADIT-CRT and RAFT trials, the
REVERSE trial enrolled patient with less advanced
LV dysfunction, with EF £ 40% and mean EF of
27%. Therefore, this study indicates that not only
patients with mild to moderate HF and EF £ 30%
(as in MADIT-CRT and RAFT) benefit from CRT.
However, the study is too small to truly determine
whether patients with EF in the range of 31–40%
truly benefit from CRT regarding HF hospitaliza-
tion or death. It would be extremely valuable to have
the entire US and European cohorts of REVERSE
patients followed for another few years to deter-
mine their long-term risk of HF or death, especial-
ly in patients with an EF of 31–40%, a subset which
was not addressed by MADIT-CRT and RAFT.
The main comparison could be done between
MADIT-CRT and RAFT, two large, phase III, de-
finitive trials with a similar design evaluating the
effect of CRT-D in mild-to-moderate HF patients.
The MADIT-CRT was the first definitive trial com-
pleted and published in 2009 [6] and its results help
establishing new Food and Drug Administration-
-approved expanded indications for CRT-D therapy.
One could ask: what have we learned from RAFT
after the publication of the MADIT-CRT trial. Both
studies showed a significant reduction in HF or
death with CRT-D therapy. However, MADIT-CRT
showed a 34% reduction during a mean 28-month
follow-up, whereas the reduction in RAFT was
25% with a 40-month follow-up. At the same time
MADIT-CRT did not show a significant mortality
benefit, whereas RAFT demonstrated a significant
25% reduction in mortality. The risk of a HF event
in the ICD-only arm was comparable in both trials:
26% in RAFT and 23% in MADIT-CRT. But the
26% mortality was much higher in RAFT ICD-only
patients when comparing to the 7% mortality in
MADIT-CRT patients randomized to the ICD-only
arm. This is a meaningful distinction even after ad-
justing for differences in the follow-up duration:
roughly over twice higher mortality despite a simi-
lar risk of HF events. What are the reasons for these
differences?
The trials were similar regarding some chara-
cteristics of the study population: mean EF, mean
QRS duration, and percentage of patients with
LBBB. However, there were several differences
between these two study populations. RAFT includ-
ed 20% of patients in NYHA class III and 80% in
Figure 3. Kaplan-Meier estimates of hospitalization for heart failure or death among patients with NYHA class II (A)
and class III (B) heart failure (reproduced from reference [10] with permission).
548
Cardiology Journal 2010, Vol. 17, No. 6
www.cardiologyjournal.org
NYHA class II, whereas MADIT-CRT included 85%
of class II and 15% class I patients. RAFT included
82% men whereas MADIT-CRT enrolled 75% men,
which may have contributed to a higher mortality
as well. The percentage of ischemic patients was
67% vs 55%, respectively, and mortality is expect-
ed to be higher in ischemic than nonischemic pa-
tients. MADIT-CRT included only sinus rhythm
patients whereas RAFT enrolled 13% patients with
atrial fibrillation and 8% patients with a paced
rhythm, factors known to characterize more ad-
vanced HF patients. Glomerular filtration rate of
< 60 mL/min/1.73 m2 was observed in 51% patients
in RAFT, whereas MADIT-CRT included 41% of
such patients; < 30 mL/min/1.73 m2 in 7% and 3%,
respectively. Patients in both trials were similarly
treated pharmacologically. Therefore, RAFT en-
rolled more advanced HF patients than MADIT-
-CRT who were more likely to die with ICD-only
therapy as well as more likely to die despite CRT-D
therapy. In fact, based on the above comparison one
could conclude that RAFT enrolled moderate-to-
-advanced HF patients whereas MADIT-CRT en-
rolled truly mild-to-moderate patients.
When comparing two-year mortality rates in
patient treated with CRT devices (based on pub-
lished Kaplan-Meier curves), RAFT showed about
20% two-year mortality in the CRT-D arm, which
is comparable with about 18% two-year mortality
in the CARE-HF, the trial enrolling class III and IV
patients, and comparable with a 25% two-year mor-
tality observed in the CRT-D arm in the COMPA-
NION trial, also enrolling class III and IV patients.
These rates are much higher than the 6% two-year
mortality observed in MADIT-CRT patients ran-
domized to CRT-D therapy.
Based on the above comparisons, RAFT seems
to be more similar to CARE-HF or COMPANION
than to MADIT-CRT, which probably explains the
differences between trials regarding the magnitude
of the effect of CRT-D on HF events and differenc-
es in the effect on mortality. Long-term follow-up
of MADIT-CRT patients will possibly allow us to
determine whether in these mild HF patients, CRT-D
also reduces mortality, which would be expected
after about a 40% reduction the risk of HF events.
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